Efficacy of Natalizumab therapy in patients of African descent With RRMS
Patients of African descent often experience a more aggressive disease course, with more frequent relapses, faster progression to a secondary progressive stage, and less robust response to Beta-interferon. In this paper a post hoc analysis was performed on two pivotal trials of Natalizumab: AFFIRM and SENTINEL trials. Forty nine patients of African descent were evaluated.
It was found that Natalizumab therapy significantly reduced the relapse rate in this population, as well as T2 lesions and gadolinium-enhancing lesions on MRI. As there is limited information on people of African descent with MS this paper would support its use as a second line therapy for those with ongoing disease activity despite treatment with Beta-interferons or glatiramer acetate.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768